SEC Filing Summary: Catalyst Biosciences, Inc. Form 10-K
Entity mismatch: The request identifies Gyre Therapeutics, Inc., but the supplied filing is for Catalyst Biosciences, Inc. This summary covers the filing’s actual registrant, Catalyst Biosciences.
Business context and reporting period
Annual report for the year ended December 31, 2021, filed March 31, 2022. Catalyst was a clinical-development biopharmaceutical company engineering protease therapeutics. During 2021 it shifted its focus from hemophilia programs to complement therapeutics. Its principal candidates were preclinical-stage CB 2782-PEG, a C3 degrader for geographic atrophy in dry AMD, and CB 4332, an engineered Complement Factor I candidate. The company had no approved products or product-sales revenue.
Financial performance and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| License and collaboration revenue | $7.3 million | $20.9 million |
| Research and development expense | $68.9 million | $53.0 million |
| General and administrative expense | $19.0 million | $16.2 million |
| Operating loss | $87.9 million | $57.4 million |
| Net loss | $87.9 million | $56.2 million |
| Cash used in operating activities | $83.8 million | $55.0 million |
Revenue in 2021 was principally reimbursed Biogen collaboration costs; 2020 included a $15.0 million upfront license payment. Collaboration costs were $7.4 million in 2021, slightly above collaboration revenue. No product gross margin was reported because there were no product sales. The filing reports $46.9 million in cash, cash equivalents and short-term investments at year-end, total assets of $55.7 million, and total liabilities of $14.6 million. Liabilities included $2.4 million of operating lease obligations; no financial borrowings are shown in the presented balance sheet. Accumulated deficit was $402.7 million. Management believed year-end resources would fund operations for at least 12 months from the filing date, while noting that estimate depended on assumptions and additional capital would be needed for development.
Material changes versus 2020
- Revenue fell 65%, chiefly because the prior year included Biogen’s upfront license payment.
- R&D expense increased 30%, including higher manufacturing and preclinical costs and a $3.8 million write-off of prepaid MarzAA manufacturing costs.
- Net loss increased 56%, and operating cash use rose from $55.0 million to $83.8 million.
- The company raised approximately $49.3 million net from a 2021 public offering. It had a $50.0 million at-the-market facility but reported no sales under it in 2021.
- Common shares outstanding increased to 31.4 million at year-end from 22.1 million a year earlier.
Outlook, risks and unusual items
- In November 2021, Catalyst halted MarzAA clinical development and restructured, including a workforce reduction of approximately 35%. It also discontinued a MarzAA manufacturing arrangement and recorded the $3.8 million write-off.
- In February 2022, the company said it was exploring strategic alternatives. In March 2022, Biogen gave notice terminating its collaboration; termination was expected to take effect in May 2022, returning CB 2782-PEG rights to Catalyst. The filing does not establish the outcome or value of a potential sale or merger.
- In March 2022, Catalyst announced a further workforce reduction, expected to leave eight full-time employees, with estimated severance and related costs of approximately $0.8 million. These are post-year-end developments, not 2021 operating results.
- Management described COVID-19-related operational and enrollment disruptions. Key risks include limited capital, dependence on third-party manufacturing, early-stage development and clinical/regulatory uncertainty, competition, and the possibility that strategic alternatives or financing may not be secured.
- The auditor issued an unqualified opinion on the financial statements. Management nevertheless reported a material weakness in contract-review controls related to accounting for employee retention bonuses, and concluded disclosure controls were not effective. Remediation was underway but not yet validated.
- The filing states that no legal proceedings were considered material. It provides annual results, not a clear standalone fourth-quarter financial breakdown.
Important facts for investors to verify
- Confirm the intended company: the supplied 10-K is Catalyst Biosciences, not Gyre Therapeutics.
- Review subsequent filings for the effective date and consequences of Biogen’s termination, CB 2782-PEG’s development plans, and any strategic transaction.
- Assess current cash, spending and runway after the announced 2022 workforce reductions and restructuring costs; the 12-month runway statement is based on year-end 2021 resources and filing-date assumptions.
- Check whether the material weakness was remediated and whether internal controls became effective.
- Verify current share count, financing activity, potential dilution and any obligations tied to licensing or manufacturing agreements.